JP2025100670A5 - - Google Patents

Info

Publication number
JP2025100670A5
JP2025100670A5 JP2025064594A JP2025064594A JP2025100670A5 JP 2025100670 A5 JP2025100670 A5 JP 2025100670A5 JP 2025064594 A JP2025064594 A JP 2025064594A JP 2025064594 A JP2025064594 A JP 2025064594A JP 2025100670 A5 JP2025100670 A5 JP 2025100670A5
Authority
JP
Japan
Prior art keywords
combination
use according
oncolytic virus
immunomodulatory agent
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025064594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025100670A (ja
Filing date
Publication date
Priority claimed from JP2018545432A external-priority patent/JP7208492B2/ja
Application filed filed Critical
Publication of JP2025100670A publication Critical patent/JP2025100670A/ja
Publication of JP2025100670A5 publication Critical patent/JP2025100670A5/ja
Pending legal-status Critical Current

Links

JP2025064594A 2016-03-10 2025-04-09 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 Pending JP2025100670A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662306470P 2016-03-10 2016-03-10
US62/306,470 2016-03-10
JP2018545432A JP7208492B2 (ja) 2016-03-10 2017-03-09 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2021148497A JP7455399B2 (ja) 2016-03-10 2021-09-13 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2023033622A JP2023060184A (ja) 2016-03-10 2023-03-06 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023033622A Division JP2023060184A (ja) 2016-03-10 2023-03-06 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法

Publications (2)

Publication Number Publication Date
JP2025100670A JP2025100670A (ja) 2025-07-03
JP2025100670A5 true JP2025100670A5 (cg-RX-API-DMAC7.html) 2025-11-11

Family

ID=59789875

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018545432A Active JP7208492B2 (ja) 2016-03-10 2017-03-09 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2021148497A Active JP7455399B2 (ja) 2016-03-10 2021-09-13 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2023033622A Pending JP2023060184A (ja) 2016-03-10 2023-03-06 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2025064594A Pending JP2025100670A (ja) 2016-03-10 2025-04-09 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018545432A Active JP7208492B2 (ja) 2016-03-10 2017-03-09 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2021148497A Active JP7455399B2 (ja) 2016-03-10 2021-09-13 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
JP2023033622A Pending JP2023060184A (ja) 2016-03-10 2023-03-06 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法

Country Status (7)

Country Link
US (3) US11497781B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426271B1 (cg-RX-API-DMAC7.html)
JP (4) JP7208492B2 (cg-RX-API-DMAC7.html)
CN (1) CN108778301A (cg-RX-API-DMAC7.html)
ES (1) ES3041500T3 (cg-RX-API-DMAC7.html)
PL (1) PL3426271T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017156349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー, インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
WO2017096201A1 (en) 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy
AU2017212713B2 (en) 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018170133A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
KR20200078483A (ko) * 2017-10-27 2020-07-01 머크 샤프 앤드 돔 코포레이션 간암 치료를 위한 조성물 및 방법
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
JP7550449B2 (ja) * 2018-04-02 2024-09-13 デューク ユニバーシティ ネオアジュバントがん治療
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
TWI787500B (zh) * 2018-04-23 2022-12-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN110819657B (zh) * 2018-08-10 2021-11-19 睿丰康生物医药科技(浙江)有限公司 一种减毒棒状病毒的制备方法及应用
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
TWI690597B (zh) * 2018-11-14 2020-04-11 國立中央大學 泌尿上皮癌的檢測套組及檢測方法
TW202600150A (zh) * 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
CA3152796A1 (en) * 2019-08-27 2021-03-04 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
KR20230012484A (ko) * 2020-05-20 2023-01-26 바이로큐어 주식회사 암 예방 또는 치료용 약학적 조성물
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム
WO2022040365A1 (en) * 2020-08-18 2022-02-24 Curators Of The University Of Missouri Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
CN114681612B (zh) * 2020-12-30 2024-10-25 苏州百迈生物医药有限公司 一种膀胱灌注药物及其制备方法和应用
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2023141229A2 (en) * 2022-01-19 2023-07-27 Istari Oncology, Inc. Oncolytic virus regimens for the treatment of cancer
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024054293A1 (en) * 2022-09-08 2024-03-14 Research Institute At Nationwide Children's Hospital Oncolytic virus combination to maximize oncolytic activity
WO2024054989A1 (en) * 2022-09-08 2024-03-14 Seneca Therapeutics, Inc. Cancer therapies with oncolytic virus and an immune checkpoint inhibitor
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles
JP2025541309A (ja) * 2022-12-15 2025-12-18 カリヴィル イムノセラピューティクス, インコーポレイテッド Cd47/sirp-アルファ免疫チェックポイント阻害剤の組成物およびその使用
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
WO2025251009A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent
WO2025251003A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US297A (en) 1837-07-29 Improvement in fire-arms
US7250A (en) 1850-04-02 Improved surface-condenser for steam-engines
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
FI961285L (fi) 1993-10-01 1996-03-20 Immunex Corp CD40:n vasta-aineita
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6432700B1 (en) 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1998039464A2 (en) 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU2003252891B2 (en) 1998-09-10 2006-06-01 Cold Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6687360B2 (en) 1999-12-30 2004-02-03 At&T Corp. Personal IP follow-me service
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
JP2004511203A (ja) 2000-03-24 2004-04-15 セル ジェネシス インコーポレーティッド 内部リボソーム接近部位を含む細胞特異的なアデノウイルスベクター
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7459154B2 (en) 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050282280A1 (en) 2003-08-28 2005-12-22 Ennist David L Oncolytic adenoviral vectors encoding GM-CSF
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
TW200607859A (en) 2004-08-23 2006-03-01 Cell Genesys Inc Oncolytic adenoviral vectors encoding GM-CSF
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
EP1877090B1 (en) 2005-05-06 2014-01-15 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
US8557257B2 (en) 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
BRPI0924123B8 (pt) 2008-12-22 2021-05-25 Oncos Therapeutics Oy vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
RU2013118723A (ru) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US9056133B2 (en) 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US10238698B2 (en) * 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013296919A1 (en) * 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
EP3461491B1 (en) 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー, インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ

Similar Documents

Publication Publication Date Title
JP7114532B2 (ja) 増強された養子細胞療法
US20250171745A1 (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
Msaouel et al. Clinical trials with oncolytic measles virus: current status and future prospects
Chiu et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Haas et al. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies
CN100387710C (zh) 原发性癌和转移性癌相关的核酸
JP2021500932A5 (cg-RX-API-DMAC7.html)
Jebar et al. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma
JP2021533789A5 (cg-RX-API-DMAC7.html)
Zolaly et al. The clinical advances of oncolytic viruses in cancer immunotherapy
JP2007511507A (ja) 癌を処置するための治療レジメン
CN111363726A (zh) 表达干扰素的溶瘤病毒及其应用
JP2020504767A (ja) 武装した複製可能な腫瘍溶解性アデノウイルス
JP2024045278A (ja) グループbアデノウイルス含有製剤
JP2022536929A5 (cg-RX-API-DMAC7.html)
CN110573624A (zh) 治疗膀胱癌的方法
JP2012516682A (ja) 非Ad5アデノウイルスベクター並びに前記に関連する方法および使用
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
Cao et al. Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: Three birds with one stone
Wang et al. Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors
AU3570299A (en) Adenovirus-chemotherapeutic combination for treating cancer
Essand et al. Oncolytic viruses for the treatment of neuroendocrine tumors
Sharma et al. Conditional replication of oncolytic virus based on detection of oncogenic mRNA
WO2025119151A1 (zh) Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用
Arguello Development of adenoviral vectors armed with TNF-related therapeutic proteins for gene therapy